Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases
23.11.2021 08:45:00 EET | Business Wire | Press release
Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases.
The agreement includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of which being eligible for milestone and royalty payments. The vaccines will combine Regeneron’s unique antigen selection expertise and innovative VelociSuite® in vivo models with Nykode Therapeutics’ modular vaccine platform and expertise in vaccine design. Nykode Therapeutics will be responsible for vaccine generation and characterization, as well as product supply through the end of Phase 1 trials. Regeneron will be responsible for antigen identification, preclinical and clinical development, manufacturing (from the end of Phase 1 trials) and commercialization.
Under the terms of the agreement, Nykode Therapeutics will receive a USD 30 million upfront payment and a USD 20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than USD 875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than USD 925 million, plus royalties. Regeneron will cover costs for research, as well as potential clinical, regulatory, manufacturing and commercialization activities.
Michael Engsig, CEO of Nykode Therapeutics, said: “We are very pleased to have entered into this groundbreaking agreement with Regeneron that may accelerate the expansion of our pipeline and fully leverage our unique and modular vaccine technology platform within multiple, large and commercially significant disease areas, in line with our corporate strategy. The agreement further validates Nykode Therapeutics’ position as a leading next-generation immunotherapy platform company. We are thrilled about the choice of programs and their therapeutic potential within cancer, and prophylactic and therapeutic potential within infectious diseases.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued: “Regeneron has generated unique know how in selecting and validating immunogenic antigens from extensive analysis of patient material. These can now be incorporated into our vaccine platform to deliver the antigens directly to antigen presenting cells and optimize the likelihood of inducing strong and broad clinically relevant immune responses. Regeneron has also developed a unique suite of proprietary VelociSuite® technologies and in vivo models that can accelerate and improve the traditional drug development process, and they will use their deep clinical expertise to guide development of these novel vaccines. Therefore, Regeneron will be a tremendous partner as we work to bring multiple additional vaccines based on our technology platform to patients in the fastest and broadest manner and complement the expansion and acceleration of internal programs.”
Mikkel W. Pedersen, Chief Scientific Officer of Nykode Therapeutics, added: “We are excited about the opportunity to work with the Regeneron team. The extensive disease biology expertise of Regeneron coupled with Nykode Therapeutics’ modular and targeted vaccine platform will enable us to design and potentially bring into the clinic new unique therapeutic vaccine concepts within both oncology and infectious diseases.”
Gavin Thurston, Ph.D., Senior Vice President, Oncology Research, at Regeneron said: “Collaborating with Nykode Therapeutics will bring another dimension to Regeneron’s already robust research and development programs for oncology and infectious disease and, in particular, provides new opportunities to help people with challenging tumor types or infectious diseases with high unmet need. Nykode Therapeutics’ platform efficiently delivers vaccine payloads to antigen presenting cells and allows for vaccine candidates that can be easily manufactured. It has already shown robust CD8+ antigen-specific T cell responses in animal models and in patients with cancer. Combining their platform with our industry-leading VelociSuite® technologies and expertise may help to accelerate this emerging and promising therapeutic approach.”
Webcast
CEO Michael Engsig and other members of management will host a webcast on November 23, 2021 at 4 p.m. CET / 10 a.m. EST to present the license and collaboration agreement with Regeneron. The slides will be made available before the webcast. The webcast may be viewed here:
https://channel.royalcast.com/landingpage/hegnarmedia/20211118_4/
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration agreement with Regeneron within oncology and infectious diseases, and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006740/en/
Contact information
Contact for Nykode Therapeutics:
CEO Michael Engsig
Nykode Therapeutics
IR@nykode.com
Nykode Therapeutics
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 13:11:00 EEST | Press release
Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and denser infrastructure are raising the bar for tower operations. Towercos need precise knowledge of each site: what
LTM Launches BlueVerse™ SovereignSphere™ Models to Help Enterprises Own Their AI Advantage23.9.2026 13:05:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today launched BlueVerse™ SovereignSphere™ Models, enabling organizations to transform proprietary knowledge into AI capabilities that understand their business context and operate within their governance boundaries. BlueVerse SovereignSphere Models enable enterprises to overcome critical AI adoption challenges by lowering infrastructure costs, simplifying governance, and reducing reliance on generic AI models. It helps organizations build AI that understands their business, language, workflows, policies, and domain expertise as a native capability. Enterprises retain ownership of their models and intellectual property while benefiting from more predictable AI economics and reduced dependence on token-heavy architectures. The key offerings in the portfolio include: Sales and Marketing Pro – Delivers CRM architect-level expertise across solution design, code generation, troubleshooting, and root-cause analysis, hel
Cox Capital Announces Tender Offers for Class I Shares of Blackstone Private Credit Fund and HPS Corporate Lending Fund23.9.2026 13:00:00 EEST | Press release
Cox Capital Partners (“Cox Capital”) announced today that Cox Capital Retail Secondaries Fund I, LP (the “Purchaser”), a private investment fund managed by an affiliate of Cox Capital, has commenced two separate cash tender offers to purchase Class I shares of Blackstone Private Credit Fund (“BCRED”) and HPS Corporate Lending Fund (“HLEND”). Both funds recently reported that their Q3 2026 repurchase programs were substantially oversubscribed. BCRED and HLEND received repurchase requests representing an estimated 10% and 11.5%, respectively, of shares outstanding. The funds’ established frameworks generally target quarterly repurchases of 5% of shares outstanding, although the amount may be increased at the discretion of the applicable fund. Cox Capital developed its secondary program to provide shareholders with an additional path to liquidity when a fund's own quarterly repurchase program does not satisfy their full request. The offers are independent of the target funds and do not mo
Three Weeks into France E-Invoicing Mandate: Sovos Hits Unparalleled Production Scale23.9.2026 11:00:00 EEST | Press release
Sovos, the agentic tax compliance company, today announced that it has surpassed 170,000 organizations registrants across the Sovos-powered network – including both Sovos-branded and partner-branded approved service providers - using Sovos technology in France. By comparison, the nearest competitors registered fewer than 2,200 organizations each. The milestone represents a significant lead in production-grade e-invoicing, with Sovos handling transaction volumes that are many multiples higher than any other tax compliance vendor operating in France. "France represents the most complex continuous transaction controls mandate the world has seen, and we entered production on day one with our Global 2000 clients fully live," said Kevin Akeroyd, CEO, Sovos. "We achieved the highest industry percentage of effective go-lives not only for these clients, but for the hundreds of technology providers who embed our e-invoicing to service hundreds of thousands of end user businesses in France. This
Mentimeter Launches Three New Tools for Better Leadership23.9.2026 10:00:00 EEST | Press release
Mentimeter is launching an engagement suite with three new tools: Menti Live, Menti Form and Menti Pulse. Through interaction, insights and recommendations, the new suite enables organizations to engage people live, collect input asynchronously and track important signals over time. Today’s launch expands Mentimeter’s platform beyond live presentations, helping turn participation into new ways of understanding what people think, know and need. “Most organizations have plenty of data, but surprisingly little understanding of what their people actually think. These new tools give leaders a way to turn participation into company-wide performance – in the room, afterward and over time. That creates better input for action and, ultimately, better leadership,” says Johnny Warström, CEO and founder of Mentimeter. Three tools for different moments of engagement Menti Form collects input asynchronously. It allows for shared reflection and gives people the opportunity to contribute regardless of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom